Chondroitin sulfate tetrasaccharides: synthesis, three-dimensional structure and interaction with midkine

Cristina Solera,^[a] Giuseppe Macchione,^[a] Susana Maza,^[a] M. Mar Kayser,^[a] Francisco Corzana,^[b] José L. de Paz,^{*[a]} Pedro M. Nieto^{*[a]}

Abstract: The biological activity of midkine, a cytokine implicated in neurogenesis and tumorigenesis, is regulated by its binding to glycosaminoglycans (GAGs) such as heparin and chondroitin sulfate (CS). To better understand the molecular recognition of GAG sequences by this growth factor, we have studied here the interactions between synthetic chondroitin sulfate-like tetrasaccharides and midkine using different techniques. First, a synthetic approach for the preparation of CS-like oligosaccharides in the sequence GalNAc-GlcA was developed. A fluorescence polarization competition assay was then employed to analyse the relative binding affinities of the synthetic compounds and revealed that midkine interacts with CS-like tetrasaccharides in the micromolar range. The 3D structure of these tetramers was studied in detail by a combination of NMR experiments and molecular dynamics simulations. Saturation transfer difference (STD) NMR experiments indicate that the CS tetrasaccharides bind to midkine in an extended conformation, with similar saturation effects along the entire sugar chain. These results are compatible with docking studies suggesting an interaction of the tetrasaccharide with midkine in a folded structure. Overall, our study gives valuable information on the interaction between midkine and well-defined, chemically synthesized CS oligosaccharides and these data can be useful for the design of more active compounds that modulate the biological function of this protein.

Introduction

Chondroitin sulfate (CS) is a linear sulfated polysaccharide that is involved in important biological processes such as central nervous system development and malaria infection.^[1] CS is formed by the repetition of disaccharide units of D-glucuronic acid (GlcA) and N-acetyl-D-galactosamine (GalNAc), following the sequence GlcA- β (1 $\rightarrow$ 3)-GalNAc- β (1 $\rightarrow$ 4), that may contain sulfate groups at different positions of the chain. CS has a high level of structural diversity due to the presence of different sulfate group distributions. The participation of CS in a wide variety of biological processes involves its interaction with

certain proteins, and these interactions require a specific arrangement of sulfate groups.^[2] CS oligosaccharide sequences, with particular sulfation motifs, are therefore responsible for protein recognition and subsequent activity. For instance, CS-E, with the disulfated sequence GlcA-GalNAc(4,6-di-OSO₃), binds to several neurotrophins, selectins and chemokines.^[3]

Midkine is a heparin-binding growth factor that promotes development, migration and survival of several types of cells.^[4] For example, midkine participates in neuronal adhesion, growth and migration, playing an important role in the development of the central nervous system. Moreover, high expression of midkine is often observed in different classes of cancer cells. This protein is also involved in inflammatory diseases. For all these reasons, midkine is a promising molecule for drug development. Midkine inhibitors^[5] may be of great value in the treatment of malignant tumors and multiple sclerosis. On the other hand, survival-promoting activity of midkine has the potential to treat and prevent neuronal degeneration processes such as Alzheimer's disease.

Heparin and chondroitin sulfate, in particular CS-E, are known to bind strongly to midkine. The dissociation constant values for both interactions are similar, falling in the nanomolar range.^[6] It is now well accepted that both polysaccharides, heparin and CS, are essential for the activity of this growth factor. As already mentioned, the interaction between CS and midkine is sensitive to the sulfation pattern and it has been demonstrated that a specific arrangement of sulfate groups, the 4,6-di-O-sulfated CS-E motif, is required for binding.^[2] However, a lot of questions remain unsolved and novel studies on the interaction between CS sequences and midkine are strongly demanded in order to discover new structure activity relationships and deepen the understanding of these molecular recognition events. For instance, it is unknown if the introduction of an additional sulfate group or the substitution of a glucuronic acid by an iduronic acid moiety in CS-E sequences, giving rise to different sulfation patterns and hybrid CS-dermatan sulfate chains respectively, can substantially affect the binding to midkine. In this context, homogeneous and structurally defined synthetic CS oligosaccharides can be very useful to study these interactions at the molecular level. Despite the recent advances in CS oligosaccharide synthesis,^[7] the development of new synthetic approaches for this type of molecules is still of great interest. Importantly, chemical synthesis can also afford CS analogues and mimetics,^[8] with non-natural sequences, that may display improved biological activities and novel therapeutic applications.

In this manuscript, we have employed synthetic CS-like oligosaccharides to study their interactions with midkine. First of all, we have carried out the total synthesis of a CS-E tetrasaccharide. This derivative was incorporated in our collection of oligosaccharide structures that includes CS

- [a] C. Solera, Dr. G. Macchione, Dr. S. Maza, M. M. Kayser, Dr. J. L. de Paz, Dr. P. M. Nieto
Glycosystems Laboratory
Instituto de Investigaciones Químicas (IIQ), cicCartuja, CSIC and Universidad de Sevilla
Americo Vespucio, 49, 41092 Sevilla, Spain
E-mail: pedro.nieto@iiq.csic.es; ilpaz@iiq.csic.es
- [b] Dr. F. Corzana
Departamento de Química, Centro de Investigación en Síntesis Química
Universidad de La Rioja
Madre de Dios, 51, 26006 Logroño, Spain

Supporting information for this article is given via a link at the end of the document.

tetramers with an iduronic acid unit at the non-reducing end instead of a GlcA, and sulfate group distributions corresponding to the CS-T subtype, characterised by the trisulfated disaccharide unit GlcA(2-OSO₃)-GalNAc(4,6-di-OSO₃).^[9] The interaction between midkine and the library of synthetic oligosaccharides was analysed using fluorescence polarization assays. We then performed a detailed analysis of the 3D structure of the CS tetrasaccharides by using a combination of NMR experiments and molecular dynamic simulations as a previous step for the subsequent STD NMR experiments and docking studies of the CS-midkine complexes.^[10]

Results and Discussion

Synthesis of a CS tetrasaccharide with the sequence GalNAc-GlcA

We have previously developed a synthetic strategy for the preparation of CS-like tetrasaccharides in the GlcA-GalNAc sequence (see below).^[11] This approach was based on the use of *N*-trifluoroacetyl (*N*-TFA) protected galactosamine building blocks.^[12] We showed that this type of GalNAc units were highly convenient for the synthesis of CS oligomers since the *N*-TFA protecting group ensures the selective formation of the required 1,2-*trans* glycosidic bond and can be easily removed at the end of the route to install the naturally occurring 2-acetamido moiety. Besides the length and the sulfation pattern, the sequence (GlcA-GalNAc or GalNAc-GlcA) is another important feature to be considered when studying the interactions between CS oligosaccharides and proteins. Here, we present the total synthesis of CS tetrasaccharide **15** with the alternative sequence GalNAc-GlcA. For this purpose, we have followed the retrosynthetic analysis shown in Scheme 1. The tetramer structure was obtained by a 2+2 coupling of disaccharide units, prepared from key compound **7**. This derivative contains a cyclic silylene group at positions 4 and 6 of the galactosamine unit that allows their selective sulfation in order to generate CS sequences with the biologically relevant E sulfation motif. Disaccharide **7** was synthesized from monosaccharides **3** and **4**^[12] that were obtained on a gram-scale from commercially available galactosamine hydrochloride and 1,2;5,6-di-*O*-isopropylidene- α -D-glucopyranose, respectively.

Scheme 1. Retrosynthetic analysis for the preparation of CS tetrasaccharide **15**.

The anomeric acetate group of compound **1**^[12] was selectively removed by treatment with hydrazine monohydrate (Scheme 2). Compound **2** was transformed into glycosyl trichloroacetimidate **3** using trichloroacetonitrile and catalytic DBU. Glycosylation reaction between donor **3** and glucuronic acid acceptor **4** afforded the desired disaccharide **5** in excellent 85% yield. Next, the protecting groups of the GalNAc moiety were rearranged to obtain key building block **7**. The protecting group distribution of this derivative allows the elongation of the oligosaccharide chain by glycosylation of the 3-OH group. The selective hydrolysis of the three acetates of compound **5** in the presence of benzoate and benzyloxycarbonyl groups was a challenging step. Triol **6** was obtained in an acceptable yield by using *p*-toluenesulfonic acid (3 equiv.) in a CH₂Cl₂/MeOH mixture.^[13] Treatment with di-*tert*-butylsilyl bistriflate in pyridine gave **7** in excellent yield. As mentioned before, the orthogonal silylene group enables the selective introduction of sulfates at the end of the synthesis. Moreover, this cyclic silyl group has several advantages over 4,6-*O*-benzylidene acetals, such as better solubility in most organic solvents and higher stability under acidic glycosylation conditions. However, it is important to note that the silylene group must be introduced at the disaccharide stage, after the formation of the GalNAc-GlcA bond, since the presence of a 4,6-di-*tert*-butylsilylene group in galactosamine (and galactose) donors leads to the predominant formation of the α glycoside, even in the presence of 2-participating groups.^[14]

Scheme 2. Reagents and conditions: a) $\text{NH}_2\text{NH}_2\cdot\text{H}_2\text{O}$, Py/AcOH, CH_2Cl_2 , 73%; b) Cl_3CCN , DBU, CH_2Cl_2 , 72%; c) **4**, TMSOTf, CH_2Cl_2 , 0°C , 85%; d) *p*-TsOH, $\text{CH}_2\text{Cl}_2/\text{MeOH}$, 52%; e) $t\text{Bu}_2\text{Si}(\text{OTf})_2$, Py, 84%.

Disaccharide **7** (Scheme 3) was converted into trichloroacetimidate **10** by levulinoylation ($\rightarrow$ **8**), followed by removal of the 4-methoxyphenyl group ($\rightarrow$ **9**) and treatment with trichloroacetonitrile and K_2CO_3 ($\rightarrow$ **10**). Thus, disaccharide **5** can be transformed, on a gram-scale, in both glycosyl donor (**10**) and acceptor (**7**), ready for 2+2 coupling reactions and assembly of growing oligosaccharide chains. Tetrasaccharide **11** was prepared by condensation of **7** and **10**. Silylene groups were then selectively removed by treatment with $(\text{HF})_n\cdot\text{Py}$ complex. Tetraol **12** was sulfated under microwave irradiation^[15] to afford **13** in excellent yield. The introduction of the sulfate groups at positions 4 and 6 of the GalNAc units, corresponding to the E sulfation pattern of chondroitin sulfate, was confirmed by ^1H and ^{13}C NMR spectroscopic data, which showed typical downfield shifts for these positions. Basic hydrolysis of ester and amide groups followed by selective *N*-acetylation gave water-soluble dibenzylated tetrasaccharide **14**. Finally, hydrogenolysis afforded fully deprotected tetramer **15** in good yield. The structure of this compound was confirmed by the analysis of the ^1H and ^{13}C NMR data that are in full agreement with those published for similar oligosaccharides. Both **15** and its dibenzylated precursor **14** were included in our library of synthetic oligosaccharides for interaction studies with midkine.

Scheme 3. Reagents and conditions: a) LevO, CH_2Cl_2 , DMAP, 87%; b) CAN, $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{CN}/\text{H}_2\text{O}$, 82%; c) Cl_3CCN , K_2CO_3 , CH_2Cl_2 , quantitative; d) **7**, TMSOTf, CH_2Cl_2 , 0°C , 54%; e) $(\text{HF})_n\cdot\text{Py}$, THF, 0°C , quantitative; f) $\text{SO}_3\cdot\text{Me}_3\text{N}$, DMF, 100°C , MW, 30 min, quantitative; g) LiOH, H_2O_2 , THF; NaOH, $\text{MeOH}/\text{H}_2\text{O}$; Ac₂O, MeOH, Et₃N, 62%; h) H_2 , Pd(OH)₂/C, $\text{H}_2\text{O}/\text{MeOH}$, 92%.

Interaction of CS tetrasaccharides with midkine by fluorescence polarization measurements

Next, we studied the interactions between midkine and our collection of chemically synthesized heparin^[16] and CS oligosaccharides (Figure 1).^[11-12] The library comprises CS-like di- and tetrasaccharides, differing in the sulfation pattern and sequence, including compounds **14** and **15**. Tetrasaccharides **16** and **17** have the alternative GlcA-GalNAc sequence and contain seven sulfate groups, a sulfation pattern corresponding to CS-T^[9a] with an additional sulfate group at position 4 of the non-reducing end. The analysis of the binding properties of these CS analogs, only accessible through chemical synthesis, is highly interesting because it has been recently reported that oligosaccharides with novel "synthetic" sulfation profiles display relevant biological properties.^[17] Compounds **18**, **19**, **20** and **21** present an L-iduronic acid (IdoA) unit at the non-reducing end of the chain, instead of a GlcA. The presence of IdoA moieties in the CS chains gives rise to the so-called hybrid chondroitin/dermatan sulfate (CS/DS) that plays a crucial role in the central nervous system development.^[9a, 18] Tetrasaccharides **18** and **19** are related to the CS-T sulfate distribution while the sulfation profile of **20** and **21** corresponds to the chondroitin sulfate E type. Synthetic heparin-like oligosaccharides **24-27**^[16] were also included in the study for comparison purposes since midkine recognizes heparin and CS-E polysaccharidic chains with similar affinities.

Figure 1. Structures of the synthetic oligosaccharides employed in the interaction studies with midkine. Throughout the paper, unit A refers to the reducing end monosaccharide.

In order to study the binding between these synthetic sugars and midkine, we have employed a competition fluorescence polarization assay, previously developed in our lab.^[12] This technique is ideal for high throughput screening, requiring very little amount of samples for the fast analysis of biomolecular interactions in solution.^[19] The relative binding affinities of the oligosaccharides were measured as their abilities to inhibit the interaction between **a protein**, midkine, and a fluorescent heparin probe. If an oligosaccharide binds to midkine, the fluorescent probe will be displaced **from the protein**, producing a decrease in the fluorescence polarization (P) value. These measurements were performed in 384-well microplates by using a standard fluorescence reader.

The correct design of a competition fluorescence polarization experiment requires the previous analysis of the fluorescence probe/protein interaction.^[19a, c] Therefore, we first measured the direct binding of the probe (a heparin hexasaccharide with a covalently linked fluorescein moiety^[12]) to midkine (Figure 2). The polarizations of samples containing a fixed concentration of probe and increasing concentrations of midkine were recorded. The obtained binding curve was fitted to the equation for a one-site binding model and the value of the dissociation constant (K_D), 44 ± 5 nM, was determined.

Figure 2. Direct binding assay for the interaction of midkine with the fluorescent probe. We recorded the polarizations (P) of wells containing a fixed concentration of probe (10 nM) and increasing concentrations of midkine (ranging from 12 nM to 750 nM). The ΔP values were obtained by subtracting the background polarization of probe solution from the polarization values of sample solutions (see experimental part). ΔP was plotted against midkine concentration and the binding curve was fitted to the equation for a one-site binding model. The plotted data are the averages of three replicate wells and the error bars represent the standard deviations.

After establishing conditions for observation of the binding between midkine and the fluorescent probe, we carried out the competition assay to screen the relative binding affinities of our library of synthetic oligosaccharides. For this purpose, we recorded the polarization of samples containing fixed concentrations of midkine (47 nM) and fluorescent probe (10 nM) in the presence of the different synthetic sugars. In competition fluorescence polarization experiments, the ratio

between the protein concentration and the K_D value for the probe/protein interaction should be at least 1. Thus, we carried out our competition assays using a midkine concentration of 47 nM. Regarding the inhibitor concentration, we performed an initial screening at 25 μ M (Figure 3). Two control samples were also included in the experiment: the first one contained only the fluorescent probe and the second one contained midkine and probe without inhibitor. The inhibition percentages shown in Figure 3 were calculated by using the polarization of these two control samples as the reference values for 100% and 0% inhibition, respectively.

Oversulfated tetrasaccharides **16**, **17**, **18** and **19** showed high inhibition of the midkine/probe interaction, indicating that these molecules strongly bound to the protein. On the contrary, compounds **14-15** and **20-21** displayed only low to moderate activity, suggesting that the number of sulfate groups is an important structural feature to be considered in midkine-oligosaccharide binding, as expected for molecular recognition processes mainly governed by electrostatic interactions. However, our results also indicate that other factors, such as the monosaccharide sequence and the presence of hydrophobic benzyl protecting groups, can also influence on the binding. In fact, comparing the activities of CS-like tetrasaccharides with four sulfate groups, we observed that **14** significantly showed the highest inhibition values.

The interaction between CS-E tetrasaccharides and midkine has been demonstrated by microarray^[2] and surface plasmon resonance^[20] experiments in which the sugars were immobilized on appropriately functionalized glass slides and gold chips, respectively. Tetrasaccharide **15** displays the same sulfation motif than the compounds employed in those experiments and we therefore expected its binding to midkine. However, **15** did not exhibit significant activity at 25 μ M concentration. We then decided to perform a second screening at a higher inhibitor concentration, 250 μ M (Figure S1, Supporting information). In this experiment, **15** bound to midkine, giving around 50% inhibition. A K_D value of 2.6 nM has been reported for the interaction between midkine and a CS-E tetrasaccharide using surface plasmon resonance.^[20] Our results point out a much weaker interaction between **15** and midkine, in the micromolar range. This discrepancy can be partially explained by the different nature of the binding experiment. Fluorescence polarization measurements evaluate the interactions in solution while SPR experiments analyse the binding that occurs at a surface on which the carbohydrate ligand was immobilized.

Figure 3. Screening assay of the synthetic oligosaccharides at 25 μ M concentration. The inhibition percentages were calculated by using the polarization of reference samples for 100% and 0% inhibition (see main text and experimental section). The data displayed are the average of two independent experiments, each one in three replicates, with error bars showing the standard deviations for these measurements.

On the other hand, Figure 3 also shows that heparin di- and tetrasaccharide did not interact with midkine at 25 μ M concentration, while heparin hexasaccharides **26** and **27** displayed more than 75% inhibition. Interestingly, the large difference in relative binding affinities between tetra- **25** and hexamers **26-27** suggests that a minimum length is required for the strong binding of heparin oligosaccharides to midkine.

CS-like tetrasaccharides that displayed more than 60% midkine inhibition were considered for detailed IC_{50} quantification. For this purpose, we measured the fluorescence polarization of wells containing a fixed concentration of midkine and probe and increasing concentrations of inhibitor (Figure S2). Polarization was then plotted against the logarithm of inhibitor concentration and the curve was fitted to the formula corresponding to a one-site competitive interaction. Table 1 shows the calculated IC_{50} values for compounds **16-19**. The differences between these values (from 2.5 μ M for **18** to 10.6 μ M for **17**) indicate that the presence of both an IdoA unit at the non-reducing end and benzyl groups at positions 3 of the uronic acid moieties slightly modify the relative binding affinities to midkine. Besides the number and position of sulfate groups, these structural modifications can also modulate the interactions with midkine. Finally, we also determined the IC_{50} value for **27** that proved to be the most potent inhibitor.

Table 1. IC_{50} values of synthetic oligosaccharides.

Compound	16	17	18	19	27
IC_{50} (μ M)	5.3	10.6	2.5	8.0	1.1

Structural analysis of tetrasaccharides

We have also performed a solution structural study for compounds **15**, **17**, **19** and **21** to be used in further structure-activity relationships. These tetrasaccharides have been studied mainly by homonuclear NMR obtaining structural restraints: torsional angles from coupling constants and distances from

NOE quantification. These experimental data were further compared with the results obtained from molecular dynamics simulations, both with and without time averaged experimental restraints. All the tetrasaccharides have temperature and base frequency dependent NMR spectra, suggesting the presence of an important conformational equilibrium. The NMR experiments for spectral assignment, as presented in the experimental part, were recorded at 323 K at 400 MHz as all the signals were detected with a narrower shape. However, the NMR experiments for 3D structural calculations were registered between 278 and 288 K in order to increase the population of the most stable conformation, to avoid potential interferences from high-energy conformations and to ensure a more favourable NOE growing regime.

We have obtained the interprotonic experimental distances from 1D and 2D NOESY experiments at variable mixing times from the cross-peaks initial growing rates at low temperatures, between 278 and 283 K, using the Isolated Spin Pair Approximation (ISPA),^[21] see experimental part. The experimental results are consistent with a general extended conformation for tetrasaccharides with the glycosidic linkages in a syn- Ψ type arrangement, detected by NOE short distances between protons at both flanks of the linkages (table 2). Coupling constants were also extracted from the spectra and mostly correspond to the canonical expected conformations for all the monosaccharide rings except for unit D of compound **21** that has different values than expected for a single chair conformation (tables S1-S4, see Supporting Information).

Table 2. NMR interprotonic distances.

	15			17				19				21		
	Exp. NMR	MD	Tar MD	Exp. NMR	MD	Tar MD	Tar MD	Exp. NMR	MD	Tar MD	Tar MD	Exp. NMR	MD	Tar MD
	500MHz 288K	500ns 300K	8ns 300K	600MHz 278K	500ns 300K	8ns 278 K	8ns 300 K	600MHz 283 K	500ns 300K	8ns 278 K	8ns 300K	600MHz 283K	500ns 300 K	10ns 300K
A1A2								3.06	3.04	4.04	3.05	3.06	3.04	3.04
A1A3	2.78	2.75	2.72	2.59	2.58	2.58	2.58 [c]	2.43	2.58	2.58	2.59 [c]	2.51	2.61	2.62
A1A5	2.17	2.51	2.33	2.59	2.58	2.58	2.58 [c]	2.43	2.58	2.59	2.57 [c]	2.48	2.58	2.58
A3A4				2.43		2.43	2.43 [d]							
A3B1				2.48	2.98	3.03	3.03 [e]	2.41	3.00	3.03	3.04 [g]			
A4A5				2.43		2.44	2.45 [d]							
A4A6								2.65	2.76	2.80	2.83	2.67	2.79	2.83
B1B2	2.38	3.04	3.04 [a]	2.48	2.35	2.33	2.34 [e]	2.41	2.34	2.34	2.45 [g]			
B1B3	2.38	2.60	2.59 [a]	2.42	2.84	2.57	2.57	2.44	2.79	2.58	2.59	2.59	2.73	2.73
B1B5	2.37	2.58	2.57	2.20	2.58	2.35	2.35	2.22	2.52	2.36	2.37	2.34	2.49	2.49
B2B3								3.05	3.01					
B2B4								2.76	2.81	2.75	2.74	2.80	2.78	2.79
B3B4	2.42	2.42	2.42					2.76	3.02			3.06		
B4B5				3.00		3.03	3.03	2.88	3.3					
B4B6	2.70	2.72	2.74											
C1B3	2.28	2.49	2.39											
C1B4				2.21	2.31	2.29	2.31	2.09	2.32	2.33	2.32	2.25	2.30	2.30
C1C2								2.53	3.04	3.04	3.04 [h]	3.05	3.04	3.04
C1C3	2.50	2.72	2.62					2.53	2.57	2.57	2.57 [h]	2.93	2.58	2.59

C1C5	2.14	2.51	2.31						2.53	2.58	2.58	2.58	^[h]	2.41	2.58	2.58
C3D1				2.40	2.35	2.32	3.32		2.48	2.34	2.35	2.32		2.22	2.35	2.37
C4C5				2.50		2.43	2.43		2.50	2.42				2.96	2.58	2.95
C4D1	2.27	2.38	2.33													
C4D5									2.66	2.51	2.48	2.57				
D1D2	2.56	3.04	3.04	^[b]					2.59	2.54	2.54	2.54		2.70	2.54	2.86
D1D3	2.56	2.59	2.57	^[b]	2.46	2.91	2.59	2.59	^[f]					2.87	4.20	2.95
D1D5	2.49	2.56	2.56		2.46	2.59	2.50	2.51	^[f]							
D2D4														2.83	4.23	2.94
D2D5														2.74	3.99	2.90
D3D4	2.42	2.42	2.42													
D4D5									2.43	2.38						

[a] Overlapping B1B2-B1B3. [b] Overlapping D1D2-D1D3. [c] Overlapping A1A3-A1A5. [d] Overlapping A4A3-A4A5. [e] Overlapping A3B1-B1B2. [f] Overlapping D1D3-D1D5. [g] Overlapping A3B1-B1B2. [h] Overlapping C1C2-C1C3-C1C5.

Next, we have performed Molecular Dynamics (MD) studies on the four compounds to have further structural information to be applied in the conformational analysis. We run MD free simulations on **17** using Glycam06 as previously reported for heparin like oligosaccharides.^[22] We did process the structures to extract geometrical values to compare with the experimental data from NMR and we have found that they agreed consistently. The coupling constants were calculated as the weighted average over the length of the whole simulation for each frame, considering the modified Altona equation for the calculated instant values.^[23] Only residue D, and in less extent B, presented some conformational flexibility that was reflected in the calculated coupling constant values that were deviated from the experimental ones (see Supporting Information, table S2). Interprotonic interresidue distances, however, were consistent with the NOE-based experimental ones (table 2). Then we decide to use time averaged distance restrained MD (tar-MD)^[24] using as experimental restrains the distances between the protons H1 to H3 and H1 to H5 of the rings B and D.^[23] In this case we obtained monoconformational behaviour for all the rings, included D (Figures 4 and 5). The coupling constant calculated from the MD-tar trajectories are now in agreement with the experimental ones that account for a stable 4C_1 conformation of the ring D, at least in a 98.2% of the trajectory when the simulation was performed at 300K. When the same MD-tar was run at 278K no evidences of conformational changes were detected at all (Table 2). Tetrasaccharide **15**, with the opposite sequence as **17**, also has monoconformational behaviour, with all the rings in 4C_1 conformation as correspond to the native unsulfated residues (Figure 5).

We then performed a similar study on **19** and **21**, both containing an IdoA unit at the non-reducing end. It is well established that iduronic acid rings usually present a typical conformational equilibrium between the chairs 1C_4 and 4C_1 and the skew-boat 2S_0 . However, the free MD of **19** showed a single conformational behaviour of the monosaccharide residues, even when the MD was launched from a 2S_0 skew-boat conformation for unit D that quickly switched to chair 1C_4 . When the time averaged restrictions were included, this behaviour was confirmed. Coupling constant analysis of the ring D also agrees with monoconformational behaviour of this ring with small coupling constant values in agreement with the experimental ones. The experimental distances are also in agreement with the results of the molecular dynamic simulations, both with and without restrictions, in which the ring D was in 1C_4 conformation (Figure 5).

Figure 4. Superimposition of the structures of tetrasaccharides **15**, **17**, **19** and **21** along 8 ns MD-tar simulations.

Figure 5. Representation of pucker coordinates (θ) of tetrasaccharides **15**, **17**, **19** and **21**. The pucker coordinates of **21** show the presence of equilibrium between conformers in the non-reducing IdoA residue.

In the case of **21**, the non-reducing end residue, an iduronate ring with three free hydroxyls, presents an intense conformational equilibrium. This can be deduced from the coupling constants that have intermediate values that do not correspond to a single conformation. The J_{HH}^3 experimental coupling values are coherent with a fast equilibrium between at least three conformations, 1C_4 , 4C_1 , and 2S_0 . Unrestrained MD simulations did not reproduce this equilibrium and the 1C_4 conformation was stable along the trajectory. Only scarce transitions to the Cremer-Pople $\theta=90^\circ$ were detected. However,

when the experimental distance between H2 and H5 (2.74 Å) was introduced as time averaged restrain on ring D, the results satisfied the experimental coupling constant data (see Supporting Information, table S4). We evaluated the results from the 10 ns tar-MD considering the canonical conformations ${}^{25}B$ and B^{30} included into the same conformational group that 2S_0 . It must be emphasised that ${}^{25}B$ and B^{30} conformations are the closest neighbours of the 2S_0 in the Cremer-Pople sphere pseudorotational equator, $\theta=90^\circ$. Then, considering the group 2S_0 as the ensemble of 2S_0 , ${}^{25}B$ and B^{30} , an 88% of the total population of the trajectory is represented and varies between 1C_4 , 4C_1 , and 2S_0 (Figure 5). In addition, the weighting averaged theoretical coupling constant values also agreed with the experimental ones.

All tetrasaccharides show an extended structure (figures 4 and 6), with Φ/Ψ maps corresponding to a syn- Φ/Ψ disposition (see Supporting Information, figures S3-S10). When time averaged restrains were applied, the space visited during the MD-tar was reduced, fitting better with the experimental values. In the case of the tetrasaccharide with the opposed sequence, **15**, this effect was even more accused, as its free MD is compatible with a more flexible compound (see Supporting Information, figures S3 and S4).

Interestingly enough, the structures of the four tetrasaccharides can be superimposed assuming the sequence inversion or shift in **15** with respect to the rest. Independently on the level of sulfation and its position, or the presence of iduronate or glucuronate residues, most of the glycosidic linkages adopt similar disposition (figure 6).

Figure 6. Superimposition of the minimized structures calculated for **15** (blue), **17** (purple), **19** (brown) and **21** (considered as two independent conformations: 1C_4 (green) and 2S_0 (yellow)).

STD and docking

The solution structure of midkine has been previously determined by NMR.^[25] Midkine is structurally divided into two domains, C- and N-terminally located, joined by a hinge region. Although heparin binding and most of the biological activities of midkine are typically associated with the C-terminal domain, recent studies^[25b] show that the N-terminal domain is also needed to mediate protein activity. For example, the interaction

with fondaparinux (a synthetic heparin pentasaccharide) involves, not only the C-terminal half, but also the N-terminal domain and the hinge. In order to better understand the process of association between the CS oligosaccharides and midkine, we have performed a STD study using **15** and **19** complexes with midkine. We have applied the initial rate of the STD amplification factors approach to better quantify the STD effects and decoupling them from spurious relaxation effects (Supporting Information, tables S5 and S6 and figures S11 and S12).^[26] Both compounds showed moderate STD effects within similar range, extended along the entire chain (Figure 7). The largest STD effects are concentrated in the reducing end residue. Unfortunately, the signal overlapping prevented us from extract more precise structural data. Together with transfer NOE cross-peaks, the results are compatible with the association of both tetrasaccharides in an extended conformation while are simultaneously bound to both midkine domains that are close in space due to the hinged structure of the protein in solution, as it can be seen in some of the NMR structures. This can be seen considering the existence of STD in both sides and along all the tetrasaccharide, in both cases.

Figure 7. STD₀ relative (top) and absolute (bottom) values for **15** and **19**.

We have performed a docking study using the coordinates of the NMR structure of midkine and the tetrasaccharides **15**, **17**, **19**

and **21** (figures S13-S17). We have chosen one of the models from the NMR structures ensemble (model 3 from 10) calculated for midkine-A (pdb code: 2LUT) in which the two binding domains are close in the 3D structure. We first have constructed the complex using AutodockTools-1.5.6 from Autodock Vina either in automatic mode (considering all the residues within 10 Å) or only the clusters described by Lim et al.^[25b]: Cluster 1: K82-R84-K105; Cluster2: Q89-K90-L92; Cluster3: R38-R47; Cluster4: K48-K50-R52; Hinge: K58-K59. The complexes thus obtained were then subjected to Flexible Docking using Glyde as implemented in Maestro suite. In all the obtained models, the tetrasaccharides interact simultaneously with both glycosaminoglycan recognition domains of midkine-A, adopting the protein a folded conformation (Figure 8). Interestingly, all the carbohydrates are in the internal region of the protein loop formed by the two recognition domains, and surrounded by the unstructured regions of midkine, explaining the STD effects seen in both faces of the oligosaccharides (Figure 8). In addition, these structures are also compatible with transfer NOE results that account for extended glycosidic linkages. Unfortunately, all the attempts to quantify the STD using CORCEMA-ST did not converge to a satisfactory structure.

Figure 8. Docking-calculated structures for complexes between midkine and the studied tetrasaccharides. Superimposition of the structures with the best docking coefficient for one representative of all the tetrasaccharides (left), superimposition of all the structures obtained using docking 10 each (right).

Conclusions

We have developed an efficient approach for the synthesis of CS oligosaccharides following the GalNAc-GlcA sequence, illustrated by the preparation of CS-E tetrasaccharide **15**. This strategy can be potentially extended to the synthesis of longer sequences with different sulfation motifs, by iterative glycosylation reactions and standard manipulation/sulfation of galactosamine 4-OH/6-OH groups, using disaccharide **7** as key building block. The present approach improves our previous strategy for CS oligomers with the alternative sequence GlcA-GalNAc, in terms of total number of steps. Thus, the crucial

cyclic silylene group, which favors the undesired 1,2-*cis* glycosidic bond, is now introduced at the disaccharide stage, after the construction of the GalNAc-GlcA 1,2-*trans* linkage.

We have also demonstrated that our fluorescence polarization competition experiment is an excellent platform for the rapid analysis of the interactions between midkine and CS-like oligosaccharides. Our results show that the binding strength mainly depends on the density of sulfate groups: the relative affinities of CS-T related structures, in the low micromolar range, are much higher than those corresponding to the CS-E tetramers. Additionally, these data suggest that other structural features of CS-like molecules, such as the presence of hydrophobic benzyl protecting groups and IdoA units instead of GlcA, can also modulate the binding to midkine. Interestingly, we have shown that midkine binds to the CS-E tetrasaccharide **15**, although with much less affinity (high micromolar range) than previously reported, probably due to the different nature of the binding experiments.

High-resolution NMR experiments provide interprotonic distances for the studied tetrasaccharides that are consistent with an extended conformation and a syn- Φ/Ψ disposition for glycosidic bonds. Experimental coupling constants values show that all the monosaccharide rings adopt single chair conformations, except residue D of tetrasaccharide **21** that presents the typical conformational equilibrium of iduronic acid units between the chairs 1C_4 and 4C_1 and the skew-boat 2S_0 . These results were confirmed with molecular dynamic simulations in which the best fit between theoretical and experimental values was obtained when time averaged restraints were applied. The binding of the CS tetrasaccharides to midkine was also evaluated by STD-NMR and docking studies. STD experiments show that the tetrasaccharides interact in an extended conformation, along the entire chain, while docking results are compatible with a simultaneous association of the sugars with both domains of midkine, in a folded protein conformation. This binding mode, mainly in the internal region of the midkine formed by the two folded domains and the hinge, is in good agreement with that previously proposed for the interaction between midkine and fondaparinux.

Experimental Section

General synthetic procedures: Thin layer chromatography (TLC) analyses were performed on silica gel 60 F₂₅₄ precoated on aluminium plates (Merck) and the compounds were detected by staining with sulfuric acid/ethanol (1:9), with cerium (IV) sulfate (10 g)/phosphomolybdic acid (13 g)/sulfuric acid (60 mL) solution in water (1 L), or with anisaldehyde solution [anisaldehyde (25 mL) with sulfuric acid (25 mL), ethanol (450 mL) and acetic acid (1 mL)], followed by heating at over 200°C. Column chromatography was carried out on silica gel 60 (0.2–0.5 mm, 0.2–0.063 mm or 0.040–0.015 mm; Merck). Optical rotations were determined with a Perkin-Elmer 341 polarimeter. 1H - and ${}^{13}C$ -NMR spectra were acquired on Bruker DPX-300, Avance III-400 and DRX-500 spectrometers. Unit A refers to the reducing end monosaccharide in the NMR data. Electrospray mass spectra (ESI MS) were carried out with an

Esquire 6000 ESI-Ion Trap from Bruker Daltonics. High resolution mass spectra (HR MS) were carried out by CITIUS (Universidad de Sevilla). Microwave-based sulfation reactions were performed using a Biotage Initiator Eight synthesizer in sealed reaction vessels.

3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido- α,β -D-galactopyranose (2): Compound **1** (2.76 g, 6.23 mmol) was dissolved in CH_2Cl_2 (25 mL) and hydrazine monohydrate (25 mL of a 0.5 M solution in Py/AcOH 3:2) was added. After stirring at room temperature for 1 h, the reaction mixture was quenched with acetone (2 mL). The mixture was diluted with CH_2Cl_2 and washed with 1 M HCl aqueous solution, saturated $NaHCO_3$ aqueous solution and H_2O . The organic layer was dried ($MgSO_4$), filtered and concentrated in vacuo. The residue was purified by column chromatography (hexane-EtOAc 2:1) to afford **2** (1.82 g, 73%). TLC (hexane-EtOAc 3:2) R_f 0.31; 1H -NMR (500 MHz, $CDCl_3$) (data for α anomer): δ 6.68 (d, 1H, $J_{NH,2} = 9.5$ Hz, NH), 5.46 (d, 1H, $J_{3,4} = 2.5$ Hz, H-4), 5.42 (d, 1H, $J_{1,2} = 4.0$ Hz, H-1), 5.34 (dd, 1H, $J_{2,3} = 11.3$ Hz, H-3), 4.60 (m, 1H, H-2), 4.48 (t, 1H, $J_{5,6a} = J_{5,6b} = 6.3$ Hz, H-5), 4.17 (m, 2H, H-6a, H-6b), 2.21, 2.09, 2.03 (3s, 9H, OAc); ${}^{13}C$ -NMR (75 MHz, $CDCl_3$): δ 171.1, 171.0, 170.4 (3CO), 157.6 (q, $COCF_3$), 115.6 (q, $COCF_3$), 91.4 (C-1), 67.8 (C-3), 67.3 (C-4), 66.6 (C-5), 62.1 (C-6), 48.7 (C-2), 20.7, 20.6, 20.4 (3CH₃); HR MS: m/z calcd for $C_{14}H_{18}F_3NO_9Na$: 424.0826; found: 424.0826 [$M+Na$] $^+$.

O-(3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido- α,β -D-galactopyranosyl) trichloroacetimidate (3): Trichloroacetonitrile (7.8 mL, 78 mmol) and catalytic DBU (78 μ L, 0.52 mmol) were added to a solution of **2** (2.08 g, 5.2 mmol) in dry CH_2Cl_2 (20 mL). After stirring for 4 h at room temperature, the reaction mixture was concentrated to dryness. The residue was purified by a short silica gel column (hexane-EtOAc 3:1 + 1% Et₃N) to afford **3** (2.04 g, 72%). TLC (hexane-EtOAc 2:1 + 1% Et₃N) R_f 0.43; 1H -NMR (300 MHz, $CDCl_3$) (data for α anomer): δ 8.85 (s, 1H, NH(TCA)), 6.59 (d, 1H, $J_{NH,2} = 9.0$ Hz, NH(TFA)), 6.47 (d, 1H, $J_{1,2} = 3.6$ Hz, H-1), 5.53 (br d, 1H, H-4), 5.35 (dd, 1H, $J_{3,4} = 3.2$ Hz, $J_{2,3} = 11.2$ Hz, H-3), 4.77 (m, 1H, H-2), 4.38 (m, 1H, H-5), 4.14 (m, 2H, H-6a, H-6b), 2.20, 2.04, 2.03 (3s, 9H, OAc); ${}^{13}C$ -NMR (75 MHz, $CDCl_3$): δ 171.1, 170.3, 170.1 (3CO), 160.1 (C=NH), 157.5 (q, $COCF_3$), 115.5 (q, $COCF_3$), 94.3 (C-1), 90.6 (CCl₃), 69.2 (C-5), 67.7 (C-3), 66.3 (C-4), 61.1 (C-6), 48.2 (C-2), 20.62, 20.59, 20.4 (3CH₃); ESI MS: m/z calcd for $C_{16}H_{18}Cl_3F_3N_2O_9Na$: 569.0; found: 569.1 [$M+Na$] $^+$.

Benzyl [4-Methoxyphenyl 2-O-benzoyl-3-O-benzyl-4-O-(3,4,6-tri-O-acetyl-2-deoxy-2-trifluoroacetamido- β -D-galactopyranosyl)- β -D-glucopyranoside] uronate (5): Donor **3** (2.02 g, 3.70 mmol) and acceptor **4** (1.40 g, 2.40 mmol) were dissolved in dry CH_2Cl_2 (30 mL) in the presence of freshly activated 4Å molecular sieves. After stirring for 15 min at 0°C, TMSOTf (134 μ L, 0.74 mmol) was added under an argon atmosphere. After stirring for 15 min at 0°C, the reaction mixture was neutralized with Et₃N, filtered and concentrated to dryness. The residue was purified by column chromatography (hexane-EtOAc 3:1→2:1) to afford **5** (1.96 g, 85%). TLC (hexane-EtOAc 2:1) R_f 0.16; $[a]_D^{20} -4^\circ$ (c 1.0, $CHCl_3$); 1H -NMR (400 MHz, $CDCl_3$): δ 7.98 (d, 2H, Ar), 7.60 (t, 1H, Ar), 7.49–7.44 (m, 7H, Ar), 7.19–7.13 (m, 5H, Ar), 6.90 (m, 2H, Ar), 6.73 (m, 2H, Ar), 6.58 (d, 1H, $J_{NH,2} = 8.8$ Hz, NH), 5.48 (dd, 1H, $J_{2,3} = 8.8$ Hz, H-2), 5.39 (d, 1H, $CH_2(Bn)$), 5.22 (d, 1H, $J_{3,4} = 2.8$ Hz, H-4'), 5.13 (d, 1H, $CH_2(Bn)$), 5.04 (d, 1H, $J_{1,2} = 7.2$ Hz, H-1), 4.87 (d, 1H, $CH_2(Bn)$), 4.68–4.62 (m, 2H, H-3', $CH_2(Bn)$), 4.25 (m, 1H, H-2'), 4.16 (t, 1H, H-4), 4.09 (m, 2H, H-1', H-5), 3.97 (dd, 1H, $J_{6a,6b} = 11.2$ Hz, H-6'a), 3.89–3.82 (m, 2H, H-3, H-6'b), 3.75 (s, 3H, Me (OMP)), 3.43 (t, 1H, $J_{5,6a} = J_{5,6b} = 7.0$ Hz, H-5'), 2.15, 2.06, 2.02 (3s, 9H, OAc); ${}^{13}C$ -NMR (100 MHz, $CDCl_3$): δ 170.4, 170.3, 170.1, 168.9, 165.0 (5CO), 157.6 (q, $COCF_3$), 155.8–114.5 (Ar), 115.8 (q, $COCF_3$), 100.8 (C-1), 100.4 (C-1'), 79.4 (C-3), 78.5 (C-4), 75.0 ($CH_2(Bn)$), 74.4 (C-5), 72.7 (C-2), 70.8, 70.6 (C-3', C-5'), 68.0 ($CH_2(Bn)$), 66.0 (C-4'), 60.6 (C-6'), 55.6 (Me (OMP)), 51.0 (C-2'), 20.7, 20.6, 20.4

(3CH₃); HR MS: *m/z* calcd for C₄₈H₄₈F₃NO₁₇Na: 990.2767; found: 990.2764 [*M*+Na]⁺.

Benzyl [4-Methoxyphenyl 2-O-benzoyl-3-O-benzyl-4-O-(2-deoxy-2-trifluoroacetamido-β-D-galactopyranosyl)-β-D-glucopyranoside]uronate (6): Compound **5** (1.96 g, 2.03 mmol) was dissolved in CH₂Cl₂/MeOH (18 mL/2 mL) and *p*-toluenesulfonic acid was added (1.16 g, 6.08 mmol). After stirring for 11 h at room temperature, the reaction mixture was diluted with CH₂Cl₂ and washed with saturated aqueous NaHCO₃ and H₂O. The organic phase was dried (MgSO₄), filtered and concentrated to dryness. The residue was purified by column chromatography (CH₂Cl₂-MeOH 40:1) to afford **6** as an amorphous white solid (884 mg, 52%). TLC (CH₂Cl₂-MeOH 30:1) R_f 0.20; [α]_D²⁰ +22° (c 1.0, CHCl₃); ¹H-NMR (500 MHz, CDCl₃): δ 8.01 (d, 2H, Ar), 7.60 (t, 1H, Ar), 7.49-7.39 (m, 8H, Ar, NH), 7.21-7.18 (m, 5H, Ar), 6.92 (m, 2H, Ar), 6.74 (m, 2H, Ar), 5.50 (t, 1H, H-2), 5.37 (d, 1H, CH₂(Bn)), 5.19 (d, 1H, CH₂(Bn)), 5.06 (d, 1H, J_{1,2} = 7.5 Hz, H-1), 4.90 (d, 1H, CH₂(Bn)), 4.63 (d, 1H, CH₂(Bn)), 4.16-4.09 (m, 2H, H-4, H-5), 3.98 (m, 2H, H-1', H-2'), 3.84 (t, 1H, J_{2,3} = J_{3,4} = 9.0 Hz, H-3), 3.80 (br s, 1H, H-4'), 3.76 (s, 3H, Me (OMP)), 3.67 (dd, 1H, J_{5,6a} = 6.0 Hz, J_{6a,6b} = 11.5 Hz, H-6'a), 3.61 (br d, 1H, H-6'b), 3.30 (br d, 1H, H-3'), 3.05 (m, 1H, H-5'); ¹³C-NMR (100 MHz, CDCl₃-CD₃OD 9:1): δ 168.0, 165.2 (2 x CO), 158.4 (q, COCF₃), 155.5-114.3 (Ar), 115.9 (q, COCF₃), 100.6 (C-1), 100.0 (C-1'), 79.7 (C-3), 76.2 (C-4), 75.8 (CH₂(Bn), C-5'), 74.2 (C-5), 72.4 (C-2), 70.8 (C-3'), 68.3 (C-4'), 67.5 (CH₂(Bn)), 61.8 (C-6'), 55.3 (Me (OMP)), 53.6 (C-2'); HR MS: *m/z* calcd for C₄₂H₄₂F₃NO₁₄Na: 864.2450; found: 864.2447 [*M*+Na]⁺.

Benzyl [4-Methoxyphenyl 2-O-benzoyl-3-O-benzyl-4-O-(4,6-O-di-*tert*-butylsilylene-2-deoxy-2-trifluoroacetamido-β-D-galactopyranosyl)-β-D-glucopyranoside]uronate (7): Compound **6** (100 mg, 0.12 mmol) was dissolved in dry Py (4 mL) and cooled (0°C). Di-*tert*-butylsilyl bis(trifluoromethanesulfonate) (42 μL, 0.13 mmol) was added and the mixture was stirred at room temperature for 25 min. The reaction was quenched with MeOH (0.5 mL), diluted with EtOAc (50 mL), and washed with 1 M HCl, saturated aqueous NaHCO₃, and H₂O. The organic phase was dried (MgSO₄), filtered and concentrated to dryness. The residue was purified by column chromatography (toluene-EtOAc 5:1) to afford **7** as a colorless oil (98 mg, 84%). TLC (toluene-EtOAc 5:1) R_f 0.29; [α]_D²⁰ +33° (c 1.0, CHCl₃); ¹H-NMR (400 MHz, CDCl₃): δ 7.94 (d, 2H, Ar), 7.60 (t, 1H, Ar), 7.46-7.38 (m, 7H, Ar), 7.22-7.07 (m, 6H, Ar, NH), 6.90 (m, 2H, Ar), 6.72 (m, 2H, Ar), 5.49 (t, 1H, H-2), 5.34 (d, 1H, CH₂(Bn)), 5.12 (d, 1H, CH₂(Bn)), 5.05 (d, 1H, J_{1,2} = 6.8 Hz, H-1), 5.00 (d, 1H, CH₂(Bn)), 4.63 (d, 1H, CH₂(Bn)), 4.30-4.18 (m, 6H, H-4, H-1', H-2', H-4', H-6'a, H-6'b), 4.14 (d, 1H, J_{4,5} = 9.2 Hz, H-5), 3.89 (t, 1H, J_{2,3} = J_{3,4} = 8.4 Hz, H-3), 3.75 (s, 3H, Me (OMP)), 3.21 (dd, 1H, J_{2,3} = 9.6 Hz, J_{3,4} = 2.8 Hz, H-3'), 3.08 (br s, 1H, H-5'), 1.09, 1.05 (2s, 18H, C(CH₃)₃); ¹³C-NMR (100 MHz, CDCl₃): δ 170.0, 165.1 (2 x CO), 158.2 (q, COCF₃), 155.7-114.5 (Ar), 116.1 (q, COCF₃), 102.0 (C-1'), 100.6 (C-1), 80.5 (C-4), 79.7 (C-3), 75.5 (CH₂(Bn)), 74.5 (C-5), 73.3 (C-3'), 73.0 (C-2), 72.1 (C-5'), 71.9 (C-4'), 68.0 (CH₂(Bn)), 66.5 (C-6'), 55.6 (Me (OMP)), 53.0 (C-2'), 27.6, 27.4 (C(CH₃)₃), 23.4, 20.6 (C(CH₃)₃); HR MS: *m/z* calcd for C₅₀H₅₈F₃NO₁₄NaSi: 1004.3471; found: 1004.3451 [*M*+Na]⁺.

Benzyl [4-Methoxyphenyl 2-O-benzoyl-3-O-benzyl-4-O-(4,6-O-di-*tert*-butylsilylene-2-deoxy-3-O-levulinoyl-2-trifluoroacetamido-β-D-galactopyranosyl)-β-D-glucopyranoside]uronate (8): Lev₂O preparation: LevOH (241 μL, 2.34 mmol) was added at 0°C to a solution of 1,3-dicyclohexylcarbodiimide (241 mg, 1.17 mmol) in CH₂Cl₂ (4 mL). After stirring 5 min at room temperature, the mixture was cooled and filtered, and the urea precipitate was washed with additional CH₂Cl₂ (2 mL), to give 6 mL of a 0.20 M Lev₂O solution.

Lev₂O (6 mL of a 0.20 M solution in CH₂Cl₂) was added at room temperature to a mixture of **7** (380 mg, 0.39 mmol) and DMAP (7 mg,

0.06 mmol). The mixture was stirred for 1 h, diluted with CH₂Cl₂, and washed with saturated aqueous NaHCO₃ and H₂O. The organic phase was dried (MgSO₄), filtered and concentrated to dryness. The residue was purified by column chromatography (toluene-EtOAc 5:1) to afford **8** as a white foam (364 mg, 87%). TLC (toluene-EtOAc 4:1) R_f 0.37; [α]_D²⁰ +30.5° (c 1.0, CHCl₃); ¹H-NMR (500 MHz, CDCl₃): δ 7.92 (d, 2H, Ar), 7.57 (t, 1H, Ar), 7.44-7.38 (m, 7H, Ar), 7.21-7.07 (m, 5H, Ar), 6.91-6.86 (m, 3H, Ar, NH), 6.70 (m, 2H, Ar), 5.46 (t, 1H, H-2), 5.30 (d, 1H, CH₂(Bn)), 5.09 (d, 1H, CH₂(Bn)), 5.05 (d, 1H, J_{1,2} = 6.8 Hz, H-1), 4.96 (d, 1H, CH₂(Bn)), 4.64 (d, 1H, CH₂(Bn)), 4.54 (m, 2H, H-2', H-3'), 4.49 (br s, 1H, H-4'), 4.40 (d, 1H, J_{1,2} = 7.7 Hz, H-1'), 4.24 (t, 1H, H-4), 4.18 (m, 2H, H-6'a, H-6'b), 4.11 (d, 1H, J_{4,5} = 9.0 Hz, H-5), 3.89 (t, 1H, J_{2,3} = J_{3,4} = 8.2 Hz, H-3), 3.73 (s, 3H, Me (OMP)), 3.06 (br s, 1H, H-5'), 2.82-2.56 (m, 4H, CH₂(Lev)), 2.20 (s, 3H, CH₃(Lev)), 1.04, 1.02 (2s, 18H, C(CH₃)₃); ¹³C-NMR (125 MHz, CDCl₃): δ 206.7, 172.7, 170.0, 165.4 (4 x CO), 157.9 (q, COCF₃), 156.0-114.8 (Ar), 116.2 (q, COCF₃), 102.3 (C-1), 100.9 (C-1), 80.4 (C-4), 79.9 (C-3), 75.4 (CH₂(Bn)), 74.9 (C-5), 74.1 (C-3'), 73.4 (C-2), 72.3 (C-5'), 69.8 (C-4'), 68.2 (CH₂(Bn)), 66.9 (C-6'), 55.9 (Me (OMP)), 50.3 (C-2'), 38.1 (CH₂(Lev)), 30.0 (CH₃(Lev)), 28.6 (CH₂(Lev)), 28.0, 27.7 (C(CH₃)₃), 23.7, 20.8 (C(CH₃)₃); HR MS: *m/z* calcd for C₅₅H₆₄F₃NO₁₆NaSi: 1102.3839; found: 1102.3842 [*M*+Na]⁺.

Benzyl [2-O-benzoyl-3-O-benzyl-4-O-(4,6-O-di-*tert*-butylsilylene-2-deoxy-3-O-levulinoyl-2-trifluoroacetamido-β-D-galactopyranosyl)-α,β-D-glucopyranose]uronate (9): CAN (2.7 mL of a 0.63 M solution in H₂O) was added to a solution of **8** (456 mg, 0.422 mmol) in CH₂Cl₂/MeCN (1:2; 24.3 mL). After stirring for 1 h at room temperature, the reaction mixture was diluted with EtOAc, washed with H₂O, saturated aqueous NaHCO₃, and H₂O. The organic phase was dried (MgSO₄), filtered and concentrated to dryness. The residue was purified by column chromatography (toluene-EtOAc 4:1) to afford **9** as an orange foam (336 mg, 82%, mixture of α/β anomers). TLC (toluene-EtOAc 4:1) R_f 0.24; ¹H-NMR (400 MHz, CDCl₃) (data for α anomer): δ 7.96 (d, 2H, Ar), 7.57 (t, 1H, Ar), 7.49-7.12 (m, 12H, Ar), 7.06 (d, 1H, J_{2,NH} = 8.3 Hz, NH), 5.55 (t, 1H, H-1), 5.41 (d, 1H, CH₂(Bn)), 5.15-5.08 (m, 2H, CH₂(Bn), H-2), 5.00 (d, 1H, CH₂(Bn)), 4.66 (d, 1H, CH₂(Bn)), 4.54-4.46 (m, 4H, H-2', H-3', H-4', H-5), 4.29 (d, 1H, J_{1,2} = 7.9 Hz, H-1'), 4.20-4.10 (m, 3H, H-3, H-6'a, H-6'b), 4.02 (t, 1H, J_{3,4} = J_{4,5} = 8.2 Hz, H-4), 3.76 (d, 1H, J_{1,OH} = 4.7 Hz, OH), 2.96 (br s, 1H, H-5'), 2.81-2.56 (m, 4H, CH₂(Lev)), 2.20 (s, 3H, CH₃(Lev)), 1.04, 1.01 (2s, 18H, C(CH₃)₃); ¹³C-NMR (100 MHz, CDCl₃) (data for α anomer): δ 206.5, 172.3, 170.7, 165.8 (4 x CO), 157.7 (q, COCF₃), 138.1-125.3 (Ar), 116.0 (q, COCF₃), 101.5 (C-1'), 90.1 (C-1), 79.9 (C-4), 76.8 (C-3), 75.2 (CH₂(Bn)), 73.7 (C-5 or C-3'), 72.2 (C-2), 71.8 (C-5'), 70.8 (C-5 or C-3'), 69.5 (C-4'), 67.8 (CH₂(Bn)), 66.5 (C-6'), 50.0 (C-2'), 37.8 (CH₂(Lev)), 29.7 (CH₃(Lev)), 28.2 (CH₂(Lev)), 27.6, 27.3 (C(CH₃)₃), 23.3, 20.5 (C(CH₃)₃); HR MS: *m/z* calcd for C₄₈H₅₈F₃NO₁₅NaSi: 996.3420; found: 996.3421 [*M*+Na]⁺.

O-[Benzyl 2-O-benzoyl-3-O-benzyl-4-O-(4,6-O-di-*tert*-butylsilylene-2-deoxy-3-O-levulinoyl-2-trifluoroacetamido-β-D-galactopyranosyl)-α,β-D-glucopyranosyluronate] trichloroacetimidate (10): Trichloroacetimidate (1.26 mL, 12.6 mmol) and K₂CO₃ (41 mg, 0.30 mmol) were added to **9** (246 mg, 0.25 mmol) in dry CH₂Cl₂ (4 mL) under an argon atmosphere. After stirring at room temperature for 8 h, the mixture was filtered and concentrated in vacuo to give **10** as a brown oil (279 mg, quantitative, mixture of α/β anomers). TLC (CH₂Cl₂-MeOH 80:1) R_f 0.67 and 0.53; ¹H-NMR (500 MHz, CDCl₃) (data for a 1:1 α/β mixture): δ 8.66, 8.62 (2s, 2H, NHα and NHβ), 7.89-7.10 (m, 31H, Ar and NH), 6.92 (br s, 1H, NH), 6.59 (d, 1H, J_{1,2} = 3.7 Hz, H-1α), 6.01 (d, 1H, J_{1,2} = 6.5 Hz, H-1β), 5.50-5.47 (m, 2H, H-2β, CH₂(Bn)), 5.39-5.34 (m, 2H, H-2α, CH₂(Bn)), 5.14 (m, 2H, CH₂(Bn)), 4.94 (d, 1H, CH₂(Bn)), 4.89 (d, 1H, CH₂(Bn)), 4.66 (m, 2H, CH₂(Bn)), 4.52-3.86 (m, 18H, H-3, H-4, H-5, H-1', H-2', H-3', H-4', H-6'a, H-6'b), 2.96 (br s, 1H, H-5'β), 2.79-2.74 (m, 4H, CH₂(Lev)), 2.69 (br s, 1H, H-5'α), 2.59 (m, 4H, CH₂(Lev)), 2.19 (2s, 6H,

CH₃(Lev)), 1.02–0.99 (2s, 36H, C(CH₃)₃); ESI MS: *m/z* calcd for C₅₀H₅₈Cl₃F₃N₂O₁₅SiNa: 1141.3; found: 1141.4 [*M*+Na]⁺.

4-Methoxyphenyl O-(4,6-O-di-*tert*-butylsilylene-2-deoxy-3-O-levulinoyl-2-trifluoroacetamido-β-D-galactopyranosyl)-(1→4)-O-(benzyl 2-O-benzoyl-3-O-benzyl-β-D-glucopyranosyluronate)-(1→3)-O-(4,6-O-di-*tert*-butylsilylene-2-deoxy-2-trifluoroacetamido-β-D-galactopyranosyl)-(1→4)-benzyl 2-O-benzoyl-3-O-benzyl-β-D-glucopyranosiduronate (11): Donor **10** (208 mg, 0.186 mmol) and acceptor **7** (71 mg, 0.072 mmol) were coevaporated with toluene, concentrated in vacuo and dissolved in dry CH₂Cl₂ (3 mL) in the presence of freshly activated 4Å molecular sieves (225 mg). After stirring for 15 min at 0 °C, TMSOTf (200 μL of a 0.19 M solution in dry CH₂Cl₂) was added under an argon atmosphere. After stirring for 30 min at 0 °C, the reaction mixture was neutralized with Et₃N, filtered, and concentrated to dryness. The residue was purified by column chromatography (CH₂Cl₂/acetone 80:1) to afford **11** as a white foam (75 mg, 54%). TLC (CH₂Cl₂-acetone 80:1) R_f 0.23; [α]_D²⁰ +19.8° (c 1.0, CHCl₃); ¹H-NMR (400 MHz, CDCl₃): δ 7.95 (m, 4H, Ar), 7.58 (m, 2H, Ar), 7.49–7.09 (m, 24H, Ar), 6.89–6.87 (m, 3H, Ar, NH), 6.69 (m, 2H, Ar), 6.51 (br d, 1H, J_{2,NH} = 8.2 Hz, NH), 5.47 (t, 1H, J_{1,2} = J_{2,3} = 7.0 Hz, H-2A or C), 5.39 (d, 1H, CH₂(Bn)), 5.27 (t, 1H, J_{1,2} = J_{2,3} = 7.4 Hz, H-2A or C), 5.18–5.07 (m, 5H, H-1A, H-1C, 3 × CH₂(Bn)), 4.89 (2d, 2H, CH₂(Bn)), 4.69 (m, 2H, H-1B or D, CH₂(Bn)), 4.56 (d, 1H, CH₂(Bn)), 4.47–4.44 (m, 4H, H-2B or D, H-4B, H-4D, H-3D), 4.35 (t, 1H, J_{3,4} = J_{4,5} = 7.8 Hz, H-4A or C), 4.18–3.95 (m, 9H, H-2B or D, H-6B, H-6D, H-1B or D, H-5A, H-5C, H-4A or C), 3.90 (t, 1H, H-3A or C), 3.83–3.76 (m, 2H, H-3B, H-3A or C), 3.73 (s, 3H, Me (OMP)), 3.00–2.86 (2 br s, 2H, H-5B, H-5D), 2.80–2.60 (m, 4H, CH₂(Lev)), 2.21 (s, 3H, CH₃(Lev)), 1.04–0.96 (m, 36H, C(CH₃)₃); ¹³C-NMR (100 MHz, CDCl₃): δ 206.3, 172.4, 169.4, 168.9, 165.1, 165.0 (6 × CO), 157.5 (2q, COCF₃), 155.5–114.3 (Ar), 117.2 (2q, COCF₃), 101.3, 101.2 (C-1B, C-1D), 100.4, 100.0 (C-1A, C-1C), 79.7, 79.6 (C-3A, C-3C), 79.3, 78.6 (C-4A, C-4C), 76.6 (C-3B), 74.6, 74.55, 74.48, 74.2 (C-5A, C-5C, CH₂(Bn)), 73.4, 73.1, 72.2, 72.1, 71.9, 71.7, 69.3 (C-5B, C-5D, C-2A, C-2C, C-4B, C-4D, C-3D), 67.9, 67.5 (CH₂(Bn)), 66.6, 66.4 (C-6B, C-6D), 55.6 (Me (OMP)), 52.1, 50.0 (C-2B, C-2D), 37.8 (CH₂(Lev)), 29.7 (CH₃(Lev)), 28.2 (CH₂(Lev)), 27.6–27.2 (C(CH₃)₃), 23.3–20.4 (C(CH₃)₃); ESI MS: *m/z* calcd for C₉₈H₁₁₄F₆N₂O₂₈Si₂Na: 1960.7; found: 1960.7 [*M*+Na]⁺.

4-Methoxyphenyl O-(2-deoxy-3-O-levulinoyl-2-trifluoroacetamido-β-D-galactopyranosyl)-(1→4)-O-(benzyl 2-O-benzoyl-3-O-benzyl-β-D-glucopyranosyluronate)-(1→3)-O-(2-deoxy-2-trifluoroacetamido-β-D-galactopyranosyl)-(1→4)-benzyl 2-O-benzoyl-3-O-benzyl-β-D-glucopyranosiduronate (12): An excess of (HF)_n-Py (110 μL, 4.2 mmol) was added at 0 °C under an argon atmosphere to a solution of **11** (41 mg, 0.021 mmol) in dry THF (2.0 mL). After 20 h at 0 °C the mixture was diluted with CH₂Cl₂ and washed with H₂O and saturated NaHCO₃ solution until neutral pH. The organic layers were dried (MgSO₄), filtered and concentrated in vacuo to give **12** (35 mg, quantitative) as a white amorphous solid. TLC (CH₂Cl₂-MeOH 20:1) R_f 0.43; ¹H-NMR (400 MHz, CDCl₃/CD₃OD 5:1): δ 7.92 (m, 4H, Ar), 7.55 (m, 2H, Ar), 7.43–7.00 (m, 24H, Ar), 6.78 (m, 2H, Ar), 6.61 (m, 2H, Ar), 5.28 (m, 2H, H-2A or C, CH₂(Bn)), 5.19 (d, 1H, CH₂(Bn)), 5.12–5.07 (m, 2H, H-2A or C, CH₂(Bn)), 5.00–4.96 (m, 2H, CH₂(Bn), H-1A or C), 4.92–4.85 (2d, 2H, CH₂(Bn)), 4.77 (d, 1H, J_{1,2} = 7.4 Hz, H-1A or C), 4.70 (dd, 1H, J_{2,3} = 11.2 Hz, J_{3,4} = 3.0 Hz, H-3D), 4.51 (m, 4H, CH₂(Bn), H-1B, H-1D), 4.32–4.17 (m, 3H, H-2D, H-4A, H-4C), 4.03–3.93 (m, 4H, H-5A, H-5C, H-4D, H-2B), 3.83–3.66 (m, 9H, H-3B, H-3A, H-3C, H-4B, 1 × H-6B, 1 × H-6D, Me (OMP)), 3.48 (dd, 1H, H-6D), 3.33 (dd, 1H, H-6B), 3.30–3.24 (m, 2H, H-5B, H-5D), 2.76–2.48 (m, 4H, CH₂(Lev)), 2.14 (s, 3H, CH₃(Lev)); ¹³C-NMR (100 MHz, CDCl₃/CD₃OD 5:1, selected data from HSQC experiment): δ 104.7, 104.5 (C-1A, C-1C), 103.7 (C-1B, C-1D), 83.8 (C-3A, C-3C), 82.8 (C-3B), 79.8 (C-4A, C-4C, 2 × CH₂(Bn)), 79.6 (C-5B, C-5D), 78.0, 77.8 (C-5A, C-5C), 76.9 (C-3D), 76.2, 76.1 (C-2A, C-2C), 71.9, 71.4 (2 × CH₂(Bn)), 71.9 (C-

4B), 69.7 (C-4D), 66.0, 65.5 (C-6B, C-6D), 59.4 (Me (OMP)), 55.9, 54.7 (C-2B, C-2D); HR MS: *m/z* calcd for C₈₂H₈₂F₆N₂O₂₈Na: 1679.4850; found: 1679.4838 [*M*+Na]⁺.

4-Methoxyphenyl O-(2-acetamido-2-deoxy-4,6-di-O-sulfo-β-D-galactopyranosyl)-(1→4)-O-(β-D-glucopyranosyluronate)-(1→3)-O-(2-acetamido-2-deoxy-4,6-di-O-sulfo-β-D-galactopyranosyl)-(1→4)-β-D-glucopyranosiduronic acid (15) Compound **12** (14 mg, 8.4 μmol) and sulfur trioxide–trimethylamine complex (47 mg, 0.34 mmol) were dissolved in dry DMF (1.5 mL) and heated at 100 °C for 30 min using microwave radiation (20 W average power). The reaction vessel was cooled and Et₃N (300 μL), MeOH (1 mL) and CH₂Cl₂ (1 mL) were added. The solution was layered on the top of a Sephadex LH 20 chromatography column which was eluted with CH₂Cl₂-MeOH (1:1) to obtain **13** as triethylammonium salt (20 mg, quantitative). TLC (EtOAc/pyridine/H₂O/AcOH 12:5:3:1) R_f 0.28; ¹H-NMR (400 MHz, CD₃OD): δ 7.98 (m, 4H, Ar), 7.63 (m, 2H, Ar), 7.51–7.07 (m, 24H, Ar), 6.84 (m, 2H, Ar), 6.72 (m, 2H, Ar), 5.45 (d, 1H, CH₂(Bn)), 5.37–5.24 (m, 5H, H-2A, H-2C, H-1A, CH₂(Bn)), 5.11 (d, 1H, CH₂(Bn)), 5.04–4.94 (m, 4H, CH₂(Bn), H-1C, H-3D), 4.87–4.81 (m, 3H, H-4D, H-4B, H-1D), 4.72 (d, 1H, J_{1,2} = 8.1 Hz, H-1B), 4.61 (d, 1H, CH₂(Bn)), 4.55–4.22 (m, 8H, CH₂(Bn), 3 × H-6B/D, H-4A, H-4C, H-2D, H-5A), 4.18–4.08 (m, 3H, H-5C, H-2B, H-6B or D), 4.03–3.96 (m, 3H, H-3B, H-3A, H-5B or D), 3.89 (t, 1H, J_{2,3} = J_{3,4} = 8.6 Hz, H-3C), 3.81 (m, 1H, H-5B or D), 3.72 (s, 3H, Me (OMP)), 3.17 (q, 24H, Et₃NH⁺), 2.84–2.59 (m, 4H, CH₂(Lev)), 2.16 (s, 3H, CH₃(Lev)), 1.28 (t, 36H, Et₃NH⁺); ¹³C-NMR (100 MHz, CD₃OD, selected data from HSQC experiment): δ 100.9 (C-1C), 99.6 (C-1A), 99.4 (C-1B), 99.3 (C-1D), 79.7 (C-3C), 79.2 (C-3A), 76.3 (C-4A, C-4C), 75.2 (C-4B), 74.9 (C-3B or C-5B or D), 74.4 (CH₂(Bn)), 74.3 (C-5C), 74.2 (C-5A), 73.7 (CH₂(Bn)), 73.2 (C-5B or D), 72.9 (C-3B or C-5B or D), 72.5 (C-2A, C-2C), 71.1 (C-4D), 70.3 (C-3D), 67.5, 67.0 (C-6B, C-6D), 67.4, 66.7 (CH₂(Bn)), 54.5 (Me (OMP)), 52.1 (C-2B), 50.5 (C-2D); ESI MS: *m/z* calcd for C₈₂H₇₉F₆N₂O₄₀NaK₂S₄: 2035.3; found: 2035.3 [*M*+Na+K+H]⁺.

H₂O₂ (30%, 0.33 mL) and an aqueous solution of LiOH (0.7 m, 0.20 mL) were added at 0 °C to a solution of **13** (20 mg, 8.4 μmol) in THF (0.9 mL). After stirring for 20 h at room temperature, MeOH (1.75 mL), H₂O (0.5 mL) and an aqueous solution of NaOH (4 m, 0.42 mL) were added. After stirring for 48 h at room temperature, the reaction mixture was neutralized with Amberlite IR-120 (H⁺) resin, filtered, and concentrated to give the desired diamine intermediate. Triethylamine (32 μL, 0.23 mmol) and acetic anhydride (32 μL, 0.34 mmol) were added to a cooled (0 °C) solution of this diamine derivative in dry MeOH (2.0 mL). After stirring for 2 h at r.t., Et₃N (300 μL) was added and the mixture was concentrated to dryness. The residue was purified by silica gel column chromatography (EtOAc-MeOH-H₂O 16:5:3 + 1% Et₃N) to give **14**. This compound was then dissolved in H₂O (2 mL) and Amberlite IR-120 H⁺ resin was added (pH = 3.0). The mixture was immediately filtered, treated with 0.04 M NaOH (pH = 7.1) and lyophilized. The white solid was finally eluted from a column of Dowex 50WX4-Na⁺ (H₂O-MeOH 9:1) to obtain **14** as sodium salt (8 mg, 62%) after lyophilization. TLC (EtOAc/pyridine/H₂O/AcOH 6:5:3:1) R_f 0.27; ¹H-NMR (400 MHz, D₂O): δ 7.54–7.29 (m, 10H, Ar), 7.04 (m, 2H, Ar), 6.91 (m, 2H, Ar), 4.95–4.93 (m, 2H, CH₂(Bn), H-1A), 4.87 (d, 1H, CH₂(Bn)), 4.77–4.67 (m, 4H, H-4B, H-4D, CH₂(Bn)), 4.59 (d, 1H, J_{1,2} = 8.2 Hz, H-1B), 4.54 (d, 1H, J_{1,2} = 8.3 Hz, H-1D), 4.44 (d, 1H, J_{1,2} = 7.6 Hz, H-1C), 4.19 (dd, 1H, J_{5,6a} = 3.6 Hz, J_{6a,6b} = 10.8 Hz, H-6B or D), 4.15–3.88 (m, 10H, 3 × H-6B/D, H-4A, H-2B, H-4C, H-2D, H-3B, H-5B, H-5D), 3.82–3.76 (m, 2H, H-5A, H-3D), 3.75 (s, 3H, Me (OMP)), 3.67 (m, 2H, H-2A, H-3A), 3.62 (d, 1H, J_{4,5} = 9.7 Hz, H-5C), 3.55 (t, 1H, J_{2,3} = J_{3,4} = 9.2 Hz, H-3C), 3.48 (t, 1H, H-2C), 2.01–2.00 (2s, 6H, NHAc); ¹³C-NMR (100 MHz, D₂O, selected data from HSQC experiment): δ 128.9–114.8 (Ar), 103.6 (C-1C), 101.1 (C-1A), 99.9 (C-1D), 99.6 (C-1B), 80.9 (C-3A, C-3C), 76.7 (C-5A), 76.6 (C-4A), 76.5–75.7 (C-4C, C-4B, C-3B, C-5C), 75.4 (C-4D), 73.8, 73.6 (CH₂(Bn)), 71.9 (C-5B, C-5D), 71.7 (C-2A), 71.3 (C-2C),

70.3 (C-3D), 67.5, 66.6 (C-6B, C-6D), 55.6 (Me (OMP)), 52.5 (C-2D), 51.3 (C-2B), 22.4 (NHAc); ESI MS: m/z calcd for $C_{49}H_{57}N_2O_{36}Na_3K_4S_4$: 1485.1; found: 1484.8 [$M+3Na+K+H$].

A solution of **14** (4.2 mg, 2.8 μ mol, sodium salt) in $H_2O/MeOH$ (3.6 mL/0.4 mL) was hydrogenated in the presence of 20% $Pd(OH)_2/C$ (9 mg). After 24 h, the suspension was filtered over celite, concentrated, and lyophilized to give **15** as a white amorphous solid (3.4 mg, sodium salt, 92%). 1H -NMR (400 MHz, D_2O): δ 7.03 (m, 2H, Ar), 6.91 (m, 2H, Ar), 4.95 (d, 1H, $J_{1,2} = 7.9$ Hz, H-1A), 4.73 (d, 1H, $J_{3,4} = 1.9$ Hz, H-4B), 4.66 (d, 1H, $J_{3,4} = 2.5$ Hz, H-4D), 4.56 (d, 1H, $J_{1,2} = 7.9$ Hz, H-1B), 4.52 (d, 1H, $J_{1,2} = 7.6$ Hz, H-1D), 4.41 (d, 1H, $J_{1,2} = 7.9$ Hz, H-1C), 4.26–4.14 (m, 4H, H-6B, H-6D), 4.08–3.99 (m, 4H, H-5B, H-5D, H-2B, H-3B), 3.87–3.76 (m, 4H, H-2D, H-3D, H-4A, H-5A), 3.74 (s, 3H, Me (OMP)), 3.72–3.64 (m, 2H, H-4C, H-3A), 3.61–3.50 (m, 3H, H-5C, H-2A, H-3C), 3.32 (t, 1H, H-2C), 1.98–1.96 (2s, 6H, NHAc); ^{13}C -NMR (100 MHz, D_2O , selected data from HSQC experiment): δ 117.9–114.6 (Ar), 103.6 (C-1C), 101.3 (C-1B, C-1D), 100.8 (C-1A), 81.6 (C-4A, C-4C), 76.3 (C-5C), 76.1 (C-5A), 75.7 (C-4B), 75.3 (C-4D), 75.0 (C-3B), 73.7 (C-3A), 73.4 (C-3C), 72.2 (C-5B, C-5D), 72.0 (C-2A), 71.9 (C-2C), 69.9 (C-3D), 67.5 (C-6B, C-6D), 55.6 (Me (OMP)), 52.2 (C-2D), 51.3 (C-2B), 22.2 (NHAc); ESI MS: m/z calcd for $C_{35}H_{44}N_2O_{36}Na_4S_4$: 644.0; found: 643.8 [$M+4Na$] $^{2+}$.

Fluorescence polarization assays

Fluorescence polarization measurements were performed in 384-well microplates (black polystyrene, non-treated, Corning). The fluorescence polarization was recorded using a TRIAD multimode microplate reader (from Dynex), with excitation and emission wavelengths of 485 and 535 nm, respectively. The fluorescent probe (a fluorescein labelled heparin-like hexasaccharide previously prepared in our lab^[12]) was dissolved in PBS buffer (10 mM, pH 7.4). Recombinant human midkine (Peprotech) was dissolved in PBS buffer (10 mM, pH 7.4) containing 1% BSA. Synthetic oligosaccharides **14–27** were dissolved in PBS buffer (10 mM, pH 7.4).

For direct binding assay between the fluorescent probe and midkine, 15 μ L of a 20 nM probe solution and 15 μ L of a series of midkine solutions, ranging from 1.5 μ M to 24 nM, were transferred to the microplate wells. The final sample volume in each well was 30 μ L. All samples were performed in replicates of three. The microplate was shaken in the dark for 5 min, before reading. Blank wells contained 15 μ L of midkine solution (1.5 μ M) and 15 μ L of PBS buffer and their measurements were subtracted from all values. Wells containing 15 μ L of the fluorescent probe solution (20 nM) and 15 μ L of PBS buffer plus 1% BSA gave the background polarization of the probe solution, in the absence of protein. The change in the fluorescence polarization (ΔP) was calculated by subtracting the background polarization of probe from the polarization value of the sample solutions. The ΔP values were plotted against midkine concentrations and the obtained binding curve was fitted to the equation for a one-site binding model $y = \Delta P_{\max}x/(K_D+x)$ where $\Delta P_{\max}$ is the maximum value approached with increasing concentrations of midkine and K_D is the dissociation constant of the probe-midkine interaction.

For the initial screening assays at a fixed concentration of inhibitor, 10 μ L of a 40 nM probe solution and 20 μ L of a 94 nM midkine solution were mixed with 10 μ L of a 100 μ M inhibitor solution. The total sample volume in each well was 40 μ L and the final buffer composition was PBS + 0.5% BSA. The final concentrations of inhibitor, fluorescent probe and midkine in each well were 25 μ M, 10 nM and 47 nM, respectively. After stirring for 5 min in the dark, fluorescence polarization was recorded. Two control samples were included in the study. The first one only contained fluorescent probe and afforded the expected value for 100% inhibition;

the second one contained midkine and probe, in the absence of inhibitor, and gave the polarization value corresponding to 0% inhibition. Blank wells contained 20 μ L of midkine solution (94 nM) and 20 μ L of PBS buffer and their measurements were subtracted from all values. All samples were performed in replicates of three.

For the determination of the IC_{50} values, we recorded the fluorescence polarization from wells containing 20 μ L of a 94 nM midkine solution and 10 μ L of a 40 nM probe solution in the presence of 10 μ L of inhibitor solution, with concentrations ranging from 100 μ M to 100 nM. The total sample volume in each well was 40 μ L and the final buffer composition was PBS + 0.5% BSA. The final concentrations of fluorescent probe and midkine in each well were 10 nM and 47 nM, respectively, while the final inhibitor concentration ranged from 25 μ M to 25 nM. The average polarization values of three replicates were plotted against the logarithm of inhibitor concentration. The curve was fitted to the equation for a one-site competition: $y = A_2 + (A_1 - A_2)/(1 + 10^{(x - \log IC_{50})})$ where A_1 and A_2 are, respectively, the maximal and minimal values of polarization, and IC_{50} is the concentration that results in 50% inhibition.

NMR Spectroscopy: NMR experiments were recorded in Bruker spectrometers of 500 and 600 MHz (Bruker Avance 500, and Bruker 600 Avance III) Fitted with inverse triple resonance probes. Samples for structural analysis were prepared in D_2O 100% at concentrations ca. 1 mM, and using low temperature (between 280 and 283 K in order to increase the population of the most stable conformation, variations were imposed by the overlapping with the residual water signal). Experiments were recorded using the gradient selected or enhanced pulse programs from the manufacturer pulse sequences library. COSY-DQF, TOSCY, and NOESY were recorded using States – TPI detection schemes in F1 and echo-antiecho with sensitivity improvement for HSQC experiments. 1D selective experiments have been acquired using 1D-DPGSE sequences for selection.^[27]

Experimental distances have been calculated using the ISPA approximation, obtaining the initial growing rates of the dipolar rate constant by fitting the growing curve of the NOE versus the mixing time to a mono exponential equation.^[21, 28]

STD-NMR experiments have been performed and STD amplification factors (STD- AF_0) were calculated from the STD initial slopes. To do so, the evolution of the STD-AF with the saturation time (t_{sat}) was fitted to the equation $STD-AF(t) = a(1 - \exp(-bt))$, where the parameter a represents the asymptotic maximum of the STD build-up curve (STD_{max}), b is a rate constant related to the relaxation properties of a given proton that measures the speed of the STD build-up (k_{sat}), and t is the saturation time (t_{sat}). Thus, the STD- AF_0 values were obtained as the product of the ab coefficients.^[26b]

Molecular Dynamics: In all cases, the starting geometries were generated from the available data^[29] deposited in the Protein Data Bank (pdb code 1hpn) and modified accordingly. The topologies were built employing the residues and the set of partial charges published by Perez et al.^[30] (the latter developed under the framework of the set of parameters for carbohydrates PIM^[31]) and the force fields *parm91*^[32] of Amber 12 and *glycam_06*^[33] together with the set of Altona parameters for sulfates^[34]. In the case of IdoA containing tetrasaccharides, two independent starting geometries were built, one with the IdoA residue in the chair 1C_4 conformation and one with the IdoA in the 2S_0 skew boat geometry. Each of these models was immersed in a 10 Å-sided cube of pre-equilibrated TIP3P water molecules.

To equilibrate the system we have followed a protocol consisting of 10 steps. Firstly, only the water molecules and ions were minimized. Then the system is heated to 300 K by a 3 ps MD simulation, allowing only water molecules and ions to move. Next, the whole system is minimized by four consecutive steps imposing positional restraints on the solute, with a force constant decreasing step by step from 20 to 5 kcal/mol. Finally, a non-restraint minimization (100 steps) is carried out.

The production dynamics simulations were accomplished at a constant temperature of 300 K (by applying the Berendsen coupling algorithm^[35] for the temperature scaling) and constant pressure (1 bar). The Particle Mesh Ewald Method^[36] (to introduce long-range electrostatic effects) and periodic boundary conditions were also turned on. The SHAKE algorithm for hydrogen atoms, which allows using a 2 fs time step, was also employed. Finally, a 9 Å cutoff was applied for the Lennard-Jones interactions.

MD simulations have been performed with the Pmemd module of Amber 12, with explicit treatment of the 10 12 hydrogen bond potential, in agreement with the parameters set for sulfates. The trajectory coordinates were saved each 0.5 ps. The overall length for the simulations was 200 – 500 ns. The data processing of the trajectories were done with the *ptraj* module of Amber 12, except for the Cremer-Pople puckering coordinates, which were calculated with the Carnal module of Amber 5.0.

The time-averaged restrained molecular dynamics were run following the above-commented protocol. In the production step, a single NOE-derived distance, between H2 and H5 protons of the IdoA residue (Table 2), was imposed as time-averaged constraint, applying an r^{-6} averaging. The equilibrium distance range was set to $r_{\text{exp}} - 0.1 \text{ Å} \leq r_{\text{exp}} \leq r_{\text{exp}} + 0.1 \text{ Å}$. Trajectories were run at 278 K, with a decay constant of 800 ps and a time step of 1 fs. The force constants r_{k2} and r_{k3} used in each case go from 25 to 45 kcal mol⁻¹ Å⁻². The overall length for the simulations was 8 ns for the tar-MD simulations. The coordinates were saved each picosecond, thus, obtaining tar MD trajectories of 8000 frames each. Convergence within the equilibrium distance range was obtained in all cases. The analysis of the tar -MD trajectories has been carried out with the *ptraj* module of AMBER 11.^[33a] This protocol has been previously discussed in detail by us.^[23]

Docking: Docking has been performed using Induced Fit Docking (IDF) as implemented in Glide module of Maestro suite.^[37] The complexes structures were constructed using the module AutodockTools 1.5.6 from Autodock Vina. The model 3 from the NMR ensemble for midkine-A deposited in the Protein Data Bank (pdb code: 2LUT) was used as model of the protein^[25b] and minimised structures taken from the MD-tar of the tetrasaccharides were used for the carbohydrate structures. The initial models were calculated using a centred box including the complete protein with a grid of 1 Å. The docking was performed considering the complete set of interactions of all the residues within 12 Å or the residues described previously as potential interacting with the ligand for midkine-B. The clusters, numbered according the 2LUT sequence, were: Cluster 1: K82-R84-K105; Cluster2: Q89-K90-L92; Cluster3: R38-R47; Cluster4: K48-K50-R52; Hinge: K58-K59. Both approximations give similar results.

A 30 Å sided cubic grid from the centroid of the ligand was generated. The ten lowest energy conformers of each ligand were submitted to flexible SP docking using Glide. The sampling of ring conformations was turned off. The penalization of the non-planar conformations for amide type torsions and the sampling of nitrogen inversions were turned on. A distance dependent dielectric constant of 4 was used and post-docking minimization was performed.

Acknowledgements

We thank the Spanish Ministry of Economy and Competitiveness (CTQ2012-32605), and the European Union (FEDER) for financial support.

Keywords: oligosaccharides • chondroitin sulfate • structure-activity relationships • carbohydrate-protein interactions • STD-NMR

- [1] a) K. Sugahara, T. Mikami, T. Uyama, S. Mizuguchi, K. Nomura and H. Kitagawa, *Curr. Opin. Struct. Biol.* **2003**, *13*, 612-620; b) R. M. Lauder, *Complement. Ther. Med.* **2009**, *17*, 56-62.
- [2] C. I. Gama, S. E. Tully, N. Sotogaku, P. M. Clark, M. Rawat, N. Vaidehi, W. A. Goddard, A. Nishi and L. C. Hsieh-Wilson, *Nat. Chem. Biol.* **2006**, *2*, 467-473.
- [3] a) C. J. Rogers, P. M. Clark, S. E. Tully, R. Abrol, K. C. Garcia, W. A. Goddard, III and L. C. Hsieh-Wilson, *Proc. Natl. Acad. Sci. U. S. A.* **2011**, *108*, 9747-9752; b) H. Kawashima, K. Atarashi, M. Hirose, J. Hirose, S. Yamada, K. Sugahara and M. Miyasaka, *J. Biol. Chem.* **2002**, *277*, 12921-12930.
- [4] a) T. Muramatsu, *Curr. Pharm. Des.* **2011**, *17*, 410-423; b) K. Kadomatsu, S. Kishida and S. Tsubota, *J. Biochem.* **2013**, *153*, 511-521.
- [5] T. Matsui, K. Ichihara-Tanaka, C. Lan, H. Muramatsu, T. Kondou, C. Hirose, S. Sakuma and T. Muramatsu, *Int. Arch. Med.* **2010**, *3*, 12-12.
- [6] S. S. Deepa, Y. Umehara, S. Higashiyama, N. Itoh and K. Sugahara, *J. Biol. Chem.* **2002**, *277*, 43707-43716.
- [7] a) J. Tamura, H. Tanaka, A. Nakamura and N. Takeda, *Tetrahedron Lett.* **2013**, *54*, 3940-3943; b) S. E. Tully, R. Mabon, C. I. Gama, S. M. Tsai, X. W. Liu and L. C. Hsieh-Wilson, *J. Am. Chem. Soc.* **2004**, *126*, 7736-7737; c) E. Bedini and M. Parrilli, *Carbohydr. Res.* **2012**, *356*, 75-85; d) C. Lopin and J. C. Jacquinot, *Angew. Chem. Int. Ed.* **2006**, *45*, 2574-2578; e) A. Vibert, C. Lopin-Bon and J. C. Jacquinot, *Chem. Eur. J.* **2009**, *15*, 9561-9578; f) J. C. Jacquinot, C. Lopin-Bon and A. Vibert, *Chem. Eur. J.* **2009**, *15*, 9579-9595; g) J. Tamura, Y. Nakada, K. Taniguchi and M. Yamane, *Carbohydr. Res.* **2008**, *343*, 39-47; h) S. Eller, M. Collot, J. Yin, H. S. Hahm and P. H. Seeberger, *Angew. Chem. Int. Ed.* **2013**, *52*, 5858-5861; i) J. C. Jacquinot and C. Lopin-Bon, *Carbohydr. Res.* **2015**, *402*, 35-43; j) K. Miyachi, M. Wakao and Y. Suda, *Bioorg. Med. Chem. Lett.* **2015**, *25*, 1552-1555.
- [8] a) S.-G. Lee, J. M. Brown, C. J. Rogers, J. B. Matson, C. Krishnamurthy, M. Rawat and L. C. Hsieh-Wilson, *Chem. Sci.* **2010**, *1*, 322-325; b) G. Despras, C. Bernard, A. Perrot, L. Cattiaux, A. Prochiantz, H. Lortat-Jacob and J.-M. Mallet, *Chem. Eur. J.* **2013**, *19*, 530-539; c) M. Rawat, C. I. Gama, J. B. Matson and L. C. Hsieh-Wilson, *J. Am. Chem. Soc.* **2008**, *130*, 2959-2961; d) P. Liu, L. Chen, J. K. C. Toh, Y. L. Ang, J.-E. Jee, J. Lim, S. S. Lee and S.-G. Lee, *Chem. Sci.* **2015**, *6*, 450-456.
- [9] a) S. Mizumoto, S. Yamada and K. Sugahara, *Curr. Opin. Struct. Biol.* **2015**, *34*, 35-42; b) R. Ramachandra, R. B. Namburi, O. Ortega-Martinez, X. Shi, J. Zaia, S. T. Dupont, M. C. Thorndyke, U. Lindahl and D. Spillmann, *Glycobiology* **2014**, *24*, 195-207.
- [10] a) G. Künze, J. P. Gehrcke, M. T. Pisabarro and D. Huster, *Glycobiology* **2014**, *24*, 1036-1049; b) A. Pichert, S. A. Samsonov, S. Theissen, L. Thomas, L. Baumann, J. Schiller, A. G. Beck-Sickinger, D. Huster and M. T. Pisabarro, *Glycobiology* **2012**, *22*, 134-145.
- [11] G. Macchione, S. Maza, M. M. Kayser, J. L. de Paz and P. M. Nieto, *Eur. J. Org. Chem.* **2014**, *2014*, 3868-3884.
- [12] S. Maza, M. Mar Kayser, G. Macchione, J. Lopez-Prados, J. Angulo, J. L. de Paz and P. M. Nieto, *Org. Biomol. Chem.* **2013**, *11*, 3510-3525.
- [13] a) A. G. Gonzalez, I. Brouard, F. Leon, J. I. Padron and J. Bermejo, *Tetrahedron Lett.* **2001**, *42*, 3187-3188; b) S.-C. Hung, X.-A. Lu, J.-C.

- Lee, M. D.-T. Chang, S.-I. Fang, T.-c. Fan, M. M. L. Zulueta and Y.-Q. Zhong, *Org. Biomol. Chem.* **2012**, *10*, 760-772.
- [14] A. Imamura, A. Kimura, H. Ando, H. Ishida and M. Kiso, *Chem. Eur. J.* **2006**, *12*, 8862-8870.
- [15] a) S. Maza, J. L. de Paz and P. M. Nieto, *Tetrahedron Lett.* **2011**, *52*, 441-443; b) G. J. Miller, S. U. Hansen, E. Avizienyte, G. Rushton, C. Cole, G. C. Jayson and J. M. Gardiner, *Chem. Sci.* **2013**, *4*, 3218-3222; c) S. U. Hansen, G. J. Miller, M. J. Cliff, G. C. Jayson and J. M. Gardiner, *Chem. Sci.* **2015**, *6*, 6158-6164.
- [16] S. Maza, G. Macchione, R. Ojeda, J. Lopez-Prados, J. Angulo, J. L. de Paz and P. M. Nieto, *Org. Biomol. Chem.* **2012**, *10*, 2146-2163.
- [17] a) M. Nonaka, X. Bao, F. Matsumura, S. Goetze, J. Kandasamy, A. Kononov, D. H. Broide, J. Nakayama, P. H. Seeberger and M. Fukuda, *Proc. Natl. Acad. Sci. U. S. A.* **2014**, *111*, 8173-8178; b) J. L. de Paz, C. Noti and P. H. Seeberger, *J. Am. Chem. Soc.* **2006**, *128*, 2766-2767.
- [18] a) K. Sugahara and T. Mikami, *Curr. Opin. Struct. Biol.* **2007**, *17*, 536-545; b) X. F. Bao, S. Nishimura, T. Mikami, S. Yamada, N. Itoh and K. Sugahara, *J. Biol. Chem.* **2004**, *279*, 9765-9776; c) C. D. Nandini, T. Mikami, M. Ohta, N. Itoh, F. Akiyama-Nambu and K. Sugahara, *J. Biol. Chem.* **2004**, *279*, 50799-50809.
- [19] a) P. Sorme, B. Kahl-Knutsson, M. Huflejt, U. J. Nilsson and H. Leffler, *Anal. Biochem.* **2004**, *334*, 36-47; b) K. Kakehi, Y. Oda and M. Kinoshita, *Anal. Biochem.* **2001**, *297*, 111-116; c) J. P. Ludeman, M. Nazari-Robati, B. L. Wilkinson, C. Huang, R. J. Payne and M. J. Stone, *Org. Biomol. Chem.* **2015**, *13*, 2162-2169; d) Y.-C. He, B.-C. Yin, L. Jiang and B.-C. Ye, *Chem. Commun.* **2014**, *50*, 6236-6239; e) C. D. Rillahan, S. J. Brown, A. C. Register, H. Rosen and J. C. Paulson, *Angew. Chem. Int. Ed.* **2011**, *50*, 12534-12537; f) Z. Han, J. S. Pinkner, B. Ford, R. Obermann, W. Nolan, S. A. Wildman, D. Hobbs, T. Ellenberger, C. K. Cusumano, S. J. Hultgren and J. W. Janetka, *J. Med. Chem.* **2010**, *53*, 4779-4792; g) D. Hauck, I. Joachim, B. Frommeyer, A. Varrot, B. Philipp, H. M. Moeller, A. Imberty, T. E. Exner and A. Titz, *ACS Chem. Biol.* **2013**, *8*, 1775-1784.
- [20] J. Tamura, N. Tsutsumishita-Nakai, Y. Nakao, M. Kawano, S. Kato, N. Takeda, S. Nakanaka and H. Kitagawa, *Bioorg. Med. Chem. Lett.* **2012**, *22*, 1371-1374.
- [21] G. M. Clore and A. M. Gronenborn, *J. Magn. Reson.* **1985**, *61*, 158-164.
- [22] J. C. Munoz-Garcia, J. Lopez-Prados, J. Angulo, I. Diaz-Contreras, N. Reichardt, J. L. de Paz, M. Martin-Lomas and P. M. Nieto, *Chem. Eur. J.* **2012**, *18*, 16319-16331.
- [23] J. C. Munoz-Garcia, F. Corzana, J. L. de Paz, J. Angulo and P. M. Nieto, *Glycobiology* **2013**, *23*, 1220-1229.
- [24] a) A. E. Torda, R. M. Scheek and W. F. Vangunsteren, *Chem. Phys. Lett.* **1989**, *157*, 289-294; b) A. E. Torda, R. M. Scheek and W. F. Vangunsteren, *J. Mol. Biol.* **1990**, *214*, 223-235; c) A. P. Nanzer, W. F. Vangunsteren and A. E. Torda, *J. Biomol. NMR* **1995**, *6*, 313-320.
- [25] a) W. Iwasaki, K. Nagata, H. Hatanaka, T. Inui, T. Kimura, T. Muramatsu, K. Yoshida, M. Tasumi and F. Inagaki, *EMBO J.* **1997**, *16*, 6936-6946; b) J. Lim, S. Yao, M. Graf, C. Winkler and D. Yang, *Biochem. J.* **2013**, *451*, 407-415.
- [26] a) M. Mayer and B. Meyer, *J. Am. Chem. Soc.* **2001**, *123*, 6108-6117; b) J. Angulo and P. M. Nieto, *Eur. Biophys. J.* **2011**, *40*, 1357-1369.
- [27] K. Stott, J. Keeler, Q. N. Van and A. J. Shaka, *J. Magn. Reson.* **1997**, *125*, 302-324.
- [28] S. Macura, B. T. Farmer and L. R. Brown, *J. Magn. Reson.* **1986**, *70*, 493-499.
- [29] B. Mulloy, M. J. Forster, C. Jones and D. B. Davies, *Biochem. J.* **1993**, *293*, 849-858.
- [30] S. Pérez, C. Meyer and A. Imberty, *Mol. Eng.* **1995**, *5*, 271-300.
- [31] M. Clark, R. D. Cramer and N. Van Opdenbosch, *J. Comput. Chem.* **1989**, *10*, 982-1012.
- [32] S. J. Weiner, P. A. Kollman, D. T. Nguyen and D. A. Case, *J. Comput. Chem.* **1986**, *7*, 230-252.
- [33] a) D. A. Case, T. A. Darden, T. E. Cheatham, C. L. Simmerling, J. Wang, R. E. Duke, R. Luo, R. C. Walker, W. Zhang, K. M. Merz, B. Roberts, S. Hayik, A. Roitberg, G. Seabra, J. Swails, A. W. Goetz, I. Kolossváry, K. F. Wong, F. Paesani, J. Vanicek, R. M. Wolf, J. Liu, X. Wu, S. R. Brozell, T. Steinbrecher, H. Gohlke, Q. Cai, X. Ye, J. Wang, M. J. Hsieh, G. Cui, D. R. Roe, D. H. Mathews, M. G. Seetin, R. Salomon-Ferrer, C. Sagui, V. Babin, T. Luchko, S. Gusarov, A. Kovalenko, and P. A. Kollman, *Amber 12*, 2012; b) R. J. Woods, R. A. Dwek, C. J. Edge and B. Fraser-Reid, *J. Phys. Chem.* **1995**, *99*, 3832-3846.
- [34] C. J. M. Huige and C. Altona, *J. Comput. Chem.* **1995**, *16*, 56-79.
- [35] H. J. C. Berendsen, J. P. M. Postma, W. F. Van Gunsteren, A. Dinola and J. R. Haak, *J. Chem. Phys.* **1984**, *81*, 3684-3690.
- [36] a) D. M. York, T. A. Darden and L. G. Pedersen, *J. Chem. Phys.* **1993**, *99*, 8345-8348; b) H. G. Petersen, *J. Chem. Phys.* **1995**, *103*, 3668-3679.
- [37] v. Schrödinger Release 2013-2: Maestro, Schrödinger, LLC, New York, NY, 2013. in *Schrödinger Release 2013-2: Maestro, version 9.5*, Schrödinger, LLC, New York, NY, 2013., Vol. **2013**.

Entry for the Table of Contents

FULL PAPER

Analysis of oligosaccharide-protein

interactions: we have studied the 3D solution structure of synthetic chondroitin sulfate tetrasaccharides and their interaction with midkine by using a combination of different techniques: fluorescence polarization, NMR spectroscopy, molecular dynamics and docking. Our results provide new information on the relationship between the chondroitin sulfate structure and its binding to midkine.

*Cristina Solera, Giuseppe Macchione,
Susana Maza, M. Mar Kayser,
Francisco Corzana, José L. de Paz,*
Pedro M. Nieto**

Page No. – Page No.

**Chondroitin sulfate tetrasaccharides:
synthesis, three-dimensional
structure and interaction with
midkine**